Targeting AKT in HER2-Negative BC

CME

Targeting AKT in HER2-Negative Breast Cancer: Implications for Future Clinical Practice

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: July 27, 2023

Expiration: July 26, 2024

Joyce O'Shaughnessy
Joyce O'Shaughnessy, MD

Activity

Progress
1
Course Completed

References

  1. D’Souza A, Spicer D, Lu J. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. J Hematol Oncol. 2018;11:80.
  2. Miricescu D, Totan A, Stanescu-Spinu II, et al. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci. 2020;22:173.
  3. Vasan N, Toska E, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann Oncol. 2019;30(suppl 10):x3-x11.
  4. Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. Nat Rev Clin Oncol. 2010;7:139-147.
  5. Martorana F, Motta G, Pavone G, et al. AKT inhibitors: New weapons in the fight against breast cancer? Front Pharmacol. 2021;12:662232.
  6. Li A, Schleicher SM, Andre F, Mitri Z. Genomic alteration in metastatic breast cancer and its treatment. Am Soc Clin Oncol Educ Book. 2020;40:1-14.
  7. Martínez-Sáez O, Chic N, Pascual T, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22:45.
  8. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-2767.
  9. Lehmann BD, Bauer J, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16:406.
  10. Wongchenko MJ, Kim SB, Saura C, et al. Circulating tumor DNA and biomarker analyses from the LOTUS randomized trial of first-line ipatasertib and paclitaxel for metastatic triple-negative breast cancer. JCO Precis Oncol. 2020;4:1012-1024.
  11. Andrikopoulou A, Chatzinikolaou S, Panourgias E, et al. The emerging role of capivasertib in breast cancer. Breast. 2022;63:157-167.
  12. Saura C, Roda D, Roselló S, et al. A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov. 2017;7:102-113.
  13. Turner NC, Oliveira M, Howell SJ, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Eng J Med. 2023;388:2058-2070.
  14. Kalinsky K, Hong F, McCourt CK, et al. Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial. JAMA Oncol. 2021;7:271-278.
  15. Howell SJ, Casbard A, Carucci M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022;23:851-864.
  16. Rugo H, Oliveira M, Howell SJ, et al. Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 1067.
  17. Turner N, Dent RA, O’Shaughnessy J, et al. Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN‑altered hormone receptor‑positive HER2‑negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res Treat. 2022;191:565-576.
  18. Schmid P, Abraham J, Chan S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol. 2019;38:423-433.
  19. Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18:1360-1372.
  20. Dent R, Kim S, Oliveira M, et al. Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. Presented at: 2020 San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS3-04.